eTheRNA Immunotherapies nv
eTheRNA Immunotherapies nv, a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and European partners to develop a novel mRNA vaccine against CoV-2 and preclinical development has started. Chinese partners may be added in the consortium in due course.
Rankings by
Национальный рейтинг8th
in Belgium Региональный рейтинг192nd
in Western Europe Глобальный рейтинг806th
worldwide